Hyperfine Inc. (HYPR)
HYPR trades on Nasdaq in Health Care, Biotechnology: Electromedical & Electrotherapeutic Apparatus. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1833769/000119312526114044/0001193125-26-114044-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HYPR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001833769 |
| SEC industry code | Electromedical & Electrotherapeutic Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $13.6M |
| Net income | -$35.6M |
| Operating income | -$37.1M |
| Net margin | -262.3% |
| Operating margin | -273.4% |
| Revenue growth | +5.2% |
| Cash | $35.1M |
| Total assets | $55.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "There can be no assurance that the Company will be able to obtain such working capital on acceptable terms or at all which could result in management concluding in the future that there is substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-09 |
| Cash and burn | $37.9M cash; operating cash flow -$6.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 106,199,172 (2026-11-04); 97,168,657 a year earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-29 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-09-18 |
| Auditor | Grant Thornton LLP, San Jose, California, United States | PCAOB Form AP 2026-03-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $48K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $6.0M | -$6.0M | -$6.1M | $37.9M | $13.4M | $19.1M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $3.9M | -$9.3M | -$7.3M | $43.5M | $13.2M | $16.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $3.9M | -$8.6M | -$9.0M | $40.8M | $13.1M | $15.3M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $5.3M | -$5.9M | -$5.2M | $35.1M | $0 | $13.6M | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $3.4M | -$11.0M | -$5.6M | $21.6M | No debt tags | $10.6M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $2.7M | -$9.2M | -$7.9M | $25.4M | No debt tags | $10.8M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $2.1M | -$9.4M | -$9.2M | $33.1M | No debt tags | $11.7M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $2.3M | -$10.4M | -$8.4M | $37.6M | No debt tags | $12.9M | 10-K 2026-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-09 |
| Latest annual report | 10-K | 2026-03-18 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 370 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.6% |
| 1 month | -26.2% |
| 3 months | -29.6% |
| Year to date | -35.8% |
| 1 year | -40.1% |
| From 52-week high | -66.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Electromedical & Electrotherapeutic Apparatus
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OM | Outset Medical Inc. | $3.39 | -9.12% | $64.0M |
| NRXS | Neuraxis Inc. | $4.80 | -11.44% | $68.1M |
| POCI | Precision Optics Corporation Inc. | $4.97 | -4.97% | $54.6M |
| STXS | Stereotaxis Inc. | $0.8027 | -4.80% | $80.4M |
| VANI | Vivani Medical Inc. Common Stock (DE) | $1.02 | +0.99% | $92.0M |
| ECOR | electroCore Inc. | $4.84 | -7.81% | $44.7M |
| HSDT | Solana Company Class A Common Stock (DE) | $1.64 | -5.20% | $103.1M |
| FOCL | EDAP TMS S.A. | $3.17 | -2.39% | $149.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier